Xenon Pharmaceuticals Inc.

By person

23 insiders · 217 transactions

2.6×

Ian Mortimer holds only 2.6 times base salary in stock. $2.09M of shares against $786.00K in salary for 2025.

Salary from the company's own proxy. The shares are what Ian Mortimer last reported holding, valued at $60.98, the price Common Shares was last bought or sold at on the open market here, on 28 Aug 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

MORTIMER IAN

PRESIDENT & CEO

$43.23K (2)

$24.82M (25) scheduled

−$24.78M

34,223

0.0353%

$2.09M

+545.7%

PIMSTONE SIMON N.

Director

$17.40K (1)

$14.96M (34)

−$14.95M

6,000

0.0062%

$365.86K

−97.2%

EMPFIELD JAMES R.

EVP, Drug Discovery

$24.82K (1)

$3.78M (5) scheduled

−$3.75M

10,000

0.0103%

$609.77K

—

ROBIN SHERRINGTON

EVP, Strategy & Innovation

—

$3.61M (11) scheduled

−$3.61M

8,398

0.0087%

$512.08K

+108.8%

BVF PARTNERS L P/IL entity

10% owner

$2.05M (28)

—

+$2.05M

59,464

0.0614%

$3.63M

−96.9%

AULIN SHERRY

Chief Financial Officer

—

$1.38M (3) scheduled

−$1.38M

0.0000%

$0.00

—

GANNON STEVEN

Director

$42.27K (1)

$1.24M (6)

−$1.20M

1,870

0.0019%

$114.03K

—

PATOU GARY

Director

$35.84K (2)

$1.17M (9) scheduled

−$1.13M

29,798

0.0308%

$1.82M

+647.6%

Svoronos Dawn

Director

$140.77K (1)

$967.50K (1)

−$826.73K

31,373

0.0324%

$1.91M

—

KENNEY CHRISTOPHER JOHN

Chief Medical Officer

$20.17K (1)

$694.76K (5) scheduled

−$674.60K

<0.0001%

$121.95

+100.0%

HOLLER FRANK A

Director

—

$649.32K (7)

−$649.32K

143,653

0.1483%

$8.76M

−1.5%

DiFabio Andrea

Chief Legal Officer

—

$230.81K (2) scheduled

−$230.81K

7,301

0.0075%

$445.19K

—

Von Seggern Christopher

Chief Commercial Officer

$97.60K (1)

—

+$97.60K

4,000

0.0041%

$243.91K

—

GAROFALO ELIZABETH A.

Director

—

$95.58K (1) scheduled

−$95.58K

2,645

0.0027%

$161.28K

—

AZAB MOHAMMAD

Director

$81.14K (5)

$214.18 (1)

+$80.93K

74,225

0.0766%

$4.53M

+1,403%

Cannon Gillian

Director

—

$63.24K (1) scheduled

−$63.24K

1,455

0.0015%

$88.72K

—

Hayden Michael R

Director

$41.25K (1)

—

+$41.25K

208,282

0.2151%

$12.70M

+169.4%

SCHELLER RICHARD H

Director

$19.95K (1)

—

+$19.95K

7,000

0.0072%

$426.84K

—

WINQUIST RAYMOND

Head, Translational Research

$3.00K (1)

—

+$3.00K

1,000

0.0010%

$60.98K

—

TARNOW MICHAEL M

Director

—

77,942

0.0805%

$4.75M

+41.3%

COHEN CHARLES J.

VP, Biology

—

6,550

0.0068%

$399.40K

—

Machado Patrick

Director

—

2,645

0.0027%

$161.28K

—

Gover Justin D.

Director

—

2,645

0.0027%

$161.28K

—

Individual transactions

Insider

Date

Role

Action

Price

Amount

KENNEY CHRISTOPHER JOHN

28 Aug 2026

Chief Medical Officer

Sold on a plan

700

$60.98

$42.68K

KENNEY CHRISTOPHER JOHN

28 Aug 2026

Chief Medical Officer

Sold on a plan

6,368

$60.17

$383.15K

Cannon Gillian

5 Jun 2026

Director

Sold on a plan

1,190

$53.14

$63.24K

PATOU GARY

5 Jun 2026

Director

Sold on a plan

1,322

$53.14

$70.25K

MORTIMER IAN

13 Mar 2026

PRESIDENT & CEO

Sold on a plan

7,308

$55.23

$403.58K

DiFabio Andrea

13 Mar 2026

Chief Legal Officer

Sold on a plan

1,342

$55.23

$74.11K

KENNEY CHRISTOPHER JOHN

13 Mar 2026

Chief Medical Officer

Sold on a plan

1,410

$55.23

$77.87K

MORTIMER IAN

10 Mar 2026

PRESIDENT & CEO

Sold on a plan

11,269

$60.11

$677.36K

DiFabio Andrea

10 Mar 2026

Chief Legal Officer

Sold on a plan

2,607

$60.11

$156.70K

KENNEY CHRISTOPHER JOHN

10 Mar 2026

Chief Medical Officer

Sold on a plan

2,771

$60.11

$166.56K

MORTIMER IAN

8 Dec 2025

PRESIDENT & CEO

Sold on a plan

2,010

$46.32

$93.10K

MORTIMER IAN

8 Dec 2025

PRESIDENT & CEO

Sold on a plan

8,820

$45.59

$402.10K

MORTIMER IAN

5 Dec 2025

PRESIDENT & CEO

Sold on a plan

14,375

$45.03

$647.31K

MORTIMER IAN

28 Nov 2025

PRESIDENT & CEO

Sold on a plan

$45.01

$4.37K

Show all 217 transactions →

Xenon Pharmaceuticals Inc.

By person

Individual transactions

What was left out